Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) insider transactions

In the twelve months to 10 November 2026, executives and directors of C4 Therapeutics reported 1 open-market sale of 10,000 shares ($22,200) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in C4 Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 October 2026Grogan Donna RoyDirectorGrant or award+4,618$3.1479,471Form 4
1 October 2026Anderson Kenneth CarlDirectorGrant or award+3,662$3.1475,612Form 4
18 September 2026Adams KendraChief Financial OfficerOption exercise+6,250—385,098Form 4
18 September 2026Adams KendraChief Financial OfficerShares withheld for tax−2,775$3.39382,323Form 4
10 July 2026Reyno LeonardChief Medical OfficerOption exercise+15,325—379,803Form 4
10 July 2026Reyno LeonardChief Medical OfficerShares withheld for tax−7,397$4.06372,406Form 4
1 July 2026Anderson Kenneth CarlDirectorGrant or award+2,650$4.3471,950Form 4
1 July 2026Grogan Donna RoyDirectorGrant or award+3,341$4.3474,853Form 4
1 June 2026Anderson Kenneth CarlDirectorOption exercise+1,070$2.1169,300Form 4
1 April 2026Grogan Donna RoyDirectorGrant or award+5,370$2.7071,512Form 4
1 April 2026Anderson Kenneth CarlDirectorGrant or award+4,259$2.7068,230Form 4
15 February 2026Hirsch AndrewPresident & CEOOption exercise+20,400—1,083,991Form 4
15 February 2026Hirsch AndrewPresident & CEOShares withheld for tax−9,057$1.891,074,934Form 4
14 February 2026Mossler MarkChief Accounting OfficerOption exercise+9,420—75,184Form 4
14 February 2026Mossler MarkChief Accounting OfficerShares withheld for tax−3,268$1.8971,916Form 4
14 February 2026Adams KendraChief Financial OfficerOption exercise+30,950—400,479Form 4
14 February 2026Adams KendraChief Financial OfficerShares withheld for tax−15,381$1.89385,098Form 4
14 February 2026Reyno LeonardChief Medical OfficerOption exercise+30,950—396,382Form 4
14 February 2026Reyno LeonardChief Medical OfficerShares withheld for tax−16,579$1.89379,803Form 4
14 February 2026Hirsch AndrewPresident & CEOOption exercise+81,725—1,123,145Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the C4 Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.